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ORIGINAL ARTICLE
Background/Aims: To examine the correlation between radiological joint damage and serological parameters in
early rheumatoid arthritis (RA).
Methods: This retrospective study reviewed the records of 216 patients diagnosed with RA and classified them
according to disease duration: group 1, ≤ 24 months; group 2, > 24 months; and group 3, all patients combined.
The extent of joint damage was assessed from plain radiographs using a modified version of the Larsen method
and compared among groups.  
Results: The mean radiographic joint damage score was significantly higher in patients who had established RA
(10.1 points) compared with those who had early RA. In group 1, the inflammatory parameters, erythrocyte
sedimentation rate, and C-reactive protein were positively correlated with the joint damage score, but rheumatoid
factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibody were not. A subgroup analysis revealed that
the anti-CCP positive patients in groups 1 and 2 had greater joint damage scores than did the anti-CCP negative
patients, but no difference in RF was observed between subgroups. Anti-CCP positivity was not significantly
correlated with joint damage sores in group 3.  
Conclusions: Anti-CCP positivity was significantly correlated with more severe joint damage at diagnosis. A
correlation was observed between the radiological joint damage score and inflammatory parameters in early and
established RA, indicating that anti-CCP can serve as a diagnostic tool and predict structural joint damage.
These findings suggest anti-CCP positive patients should receive aggressive therapeutic intervention. (Korean J
Intern Med 2010;25:201-206)
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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory
disease of the joints that affects approximately 0.5% to
1% of the general population [1]. The clinical manifestation
and disease progress is heterogeneous. Immunologically
mediated inflammation of the synovium causes cartilage
destruction and bony erosion that can result in permanent
disability. Thus, early diagnosis and treatment with
disease-modifying antirheumatic drugs (DMARDs) is
necessary to prevent joint destruction and deformity and
to preserve function.
Rheumatoid factor (RF) has been the only serologic
marker in the American College of Rheumatology (ACR)
classification criteria for several decades [2]. RF is a valid
prognostic indicator, but the antibody’s usefulness for
early detection of RA is limited by its moderate sensitivity
and relatively low specificity [3].   
In recent years, the antibody to cyclic citrullinated
peptide (anti-CCP) has been shown to be more specificthan and as sensitive as RF for diagnosing RA [3,4].
Anti-CCP belongs to a family of anti-filaggrin antibodies
that react with the antigenic determinant that contains
citrullinated arginine residues [5]. 
Studies indicating that anti-CCP is a better diagnostic
tool than RF have been reported for several years [6,7].
Anti-CCP has a sensitivity of 40% to 80%, a specificity of
81% to 100% [7], and an excellent positive and negative
predictive value for RA diagnosis [6,7]. These features
highlight the antibody’s value for monitoring the patho-
genesis of RA [8]. The presence of anti-CCP is associated
with a higher Larsen score at baseline and at follow up,
and it predicts radiological joint damage in early RA [4,9-
11]. Furthermore, anti-CCP has been shown to predict a
change in the Larsen score and poor functional response
in patients who were RF negative [12]. These findings
suggest that the presence of anti-CCP is as reliable a
predictor of future joint damage as is RF.
The present study compared the relationship between
joint damage and parameters such as RF and anti-CCP in
early RA patients.
METHODS
Patients
This retrospective study reviewed the records of 216
patients who were diagnosed with RA using the ACR
criteria [2] and were treated using DMARDs and/or
steroids. All patients were over 18 years of age and had
been diagnosed with RA for at least 3 months. 
The patients were classified into three groups: group 1
had a disease duration ≤ 24 months, group 2 had a
disease duration between 25 and 48 months, and group
3 was the aggregate of all patients.
Laboratory tests
Several serological markers, erythrocyte sedimentation
rate (ESR), C-reactive protein (CRP), RF, and anti-CCP
measured at the time of diagnosis were examined. RF was
measured by immunoturbidimetry using Cobas integra
RFII (Roche Diagnostics GmbH, Mannheim, Germany)
and anti-CCP was measured by enzyme linked immunosor-
bent assay (ELISA) using DIASTATTM (Axis-Shield
Diagnostics, Dundee, UK).
Radiological evaluation of joint damage
A radiologist and rheumatologist evaluated joint
damage on plain films of the hand or wrist taken at the
time of diagnosis using the modified version of the Larsen
method [13]. This method reviews plain films of eight
proximal interphalangeal joints, two interphalangeal
thumb joints, 10 metacarpophalangeal joints, and both
wrists. The degree of joint damage was graded as follows:
grade 0, normal; grade 1, soft tissue swelling, joint space
narrowing, and subchondral osteopenia; grade 2, bone
erosion with destruction of < 25% of the joint space; grade
3, 26% to 50% joint space destruction; grade 4, 51% to
75% destruction; and grade 5, > 75% destruction of the
joint space. The sum of all scores equaled 110 points. We
examined the correlation between the serological parameters
and the joint damage score. Scoring reliability was evaluated
using the intraclass correlation coefficient 0.96 (95%
confidence interval, 0.92 to 0.99). 
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Table 1. Patient characteristics
Characteristics Duration ≤ 24 mon Duration > 24 mon p value
Patients, n 110 106 0.563
Mean age, yr (SD) 48.80 (13.38) 52.07 (11.59) 0.057
Female (%) / Male (%) 78 (70.9) / 32 (29.1) 88 (83) / 18 (17) 0.035a 
Mean disease duration, mon (SD) 7.89 (6.03) 89.04 (78.69) 0.000a
RF, IU/mL (SD) 148.48 (181.22) 139.97 (165.42) 0.719
Anti-CCP, U/mL (SD)  58.15 (42.36) 62.29 (43.59) 0.480
ESR, mm (SD) 37.73 (27.09) 38.12 (31.24) 0.922
CRP, mg/L (SD) 13.81 (23.69) 14.77 (21.43) 0.241
Joint damage score (SD) 4.95 (2.52) 10.14 (6.90) 0.000a
SD, standard deviation; RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; ESR, erythrocyte sedimentation rate; CRP, C-
reactive protein.
ap < 0.05.Statistical analysis
SPSS version 14.0 (SPSS Inc., Chicago, IL, USA) was
used for the statistical analysis. The two-sample t test and
chi-squared test were used for between-group comparisons.
The correlation between the radiological joint damage
score and each serological parameter was evaluated using
Pearson’s correlation coefficient. All p values < 0.05 were
deemed to be statistically significant. The results are
expressed as mean and standard deviation.
RESULTS
Table 1 shows the patient characteristics. The disease
duration and joint damage scores were significantly higher
in group 2. Additionally, the number of men in group 1
was significantly higher compared with that in group 2.
There was no statistical difference in RF, anti-CCP level,
inflammatory parameters  between groups. 
The joint damage score was correlated with CRP and
ESR in all groups, but it was only correlated with disease
duration in the established RA and combined groups
(Table 2). 
A subgroup analysis of RF and anti-CCP positive and
negative patients revealed no difference in the joint
damage score between RF positive and negative patients.
In contrast, the joint damage score in groups 1 and 2 was
significantly higher in the anti-CCP positive patients
compared with the anti-CCP negative patients (Table 3)
No correlation was found between the joint damage score
and the anti-CCP positivity in group 3 (p = 0.07). These
results are illustrated in Fig. 1.
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Table 2. Correlations between the joint damage score and clinical parameters
Parameters Group 1 Group 2 Group 3
(duration ≤ 24 mon) (duration > 24 mon) (aggregate)
RF, IU/mL   0.15 (0.12 a) 0.03 (0.80 a) 0.04 (0.59 a)
Anti-CCP, U/mL  0.01 (0.92) 0.17 (0.08) 0.13 (0.07)
CRP, mg/L  0.31 (< 0.05 b) 0.25 (< 0.05 b) 0.25 (< 0.05 b)
ESR, mm  0.29 (< 0.05 b) 0.44 (< 0.05 b) 0.34 (< 0.05 b)
Mean disease duration, mon 0.05 (0.64) 0.36 (< 0.05 b) 0.51 (< 0.05 b)
RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate.
aPearson’s correlation coefficient (p value).
bp < 0.05.
A B Anti-CCP RF
Figure 1. Comparison of the mean joint damage score in anti-CCP positive and negative patients (A) and RF positive and negative
patients (B). Both the open circles and asterisks indicate values beyond 2 standard deviation of the mean value. Anti-CCP, anti-cyclic
citrullinated peptide; RF, rheumatoid factor.DISCUSSION
RA is characterized by chronic inflammation of
the joints that causes structural and functional damage.
The disease affects 0.5% to 1% of the general population
[1]. The etiology of RA is not fully understood; however,
genetic predisposition and environmental factors such as
smoking may contribute to the etiopathogenesis [14].
Joint destruction that occurs as the disease progresses
decreases the quality of life and increases the socioeconomic
burden. Thus, early diagnosis and initiation of a therapeutic
intervention is critical for a good prognosis [15,16].
The ACR classification criteria for RA consist primarily
of clinical symptoms, and RF is the only serological test
[2]. A shortcoming of these criteria is that it is difficult to
make a definitive diagnosis until the disease has progressed
to the extent that synovial inflammation has caused joint
damage. 
RF is an autoantibody to the Fc fragment of immunoglob-
ulin G. The effectiveness of the antibody as a diagnostic
marker has been questioned because of its unsatisfactory
sensitivity and specificity [3,17,18].
Recent reports have suggested that early initiation of
therapeutic interventions, including DMARDs, can slow
joint damage [19-22]. However, the characteristic clinical
features of RA are often not apparent early in the disease
process, and therapy is not initiated until considerable
time has elapsed and joint damage has appeared. Despite
this, RF is included in the diagnostic criteria because it is
an indicator of joint damage and level of disability and can
be easily tested. 
Antiperinuclear factor and anti-keratin antibody are
anti-filaggrin antibodies that have a high specificity for
RA, but they are not used to diagnose the disease because
of difficult technical requirements [23-25].
Recently, anti-CCP has been used to diagnose RA. Arginine
residues are converted to citrulline by peptidylarginine
deiminase (PAD), and the autoantibody, anti-CCP, reacts
with the substrate [26].
Avouac et al. [7] reported that anti-CCP has a diagnostic
sensitivity of 39% to 94% and a specificity of 81% to 100%
for RA. The autoantibody is closely related to the evolution
of RA from undifferentiated arthritis and has a higher
sensitivity than does RF for predicting the development of
RA in normal healthy controls. 
This high specificity suggests that anti-CCP is related
to the etiopathogenesis of RA. Suzuki et al. [8] suggested
that one haplotype of PAD, type 4, is found more often in
people who have RA than in the normal population, sug-
gesting that proteins in RA patients are readily citrullinated
and that these proteins cause an autoimmune reaction in
the joint cavity. Caspi et al. [27] reported finding higher
levels of anti-CCP in the synovial fluid of patients who had
RA than in patients who had osteoarthritis or psoriatic
arthritis.
Forslind et al. [4] reported that anti-CCP was correlated
with a high baseline and 2-year Larsen score in a 2-year
follow up of 397 early RA patients who had a disease
duration < 1 year.
In the present study, the joint damage score was
significantly higher in the anti-CCP positive group than it
was in the RF positive group (Table 3). We did not
determine the correlation between anti-CCP and the joint
damage score; however, the degree of erosive joint damage
was significantly higher in patients positive for anti-CCP
compared with anti-CCP negative patients in early and
established RA. A prospective study is required to
determine the prognostic power of anti-CCP. 
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Table 3. Comparison of mean joint damage score in RF positive and negative patients and anti-CCP positive and
negative patients
Group 1 (duration ≤ 24 mon) Group 2 (duration > 24 mon) Group 3 (aggregate)
RF, IU/mL Anti-CCP, U/mL RF, IU/mL Anti-CCP, U/mL RF, IU/mL Anti-CCP, U/mL
(+) (-) (+) (-) (+) (-) (+) (-) (+) (-) (+) (-)
Patients, n 97 13 93 17 96 10 83 23 193 23 176 40
Mean joint  5.05 4.15  5.15  3.82  10.35 8.10  10.86  7.57 7.69 5.87 7.84 5.98 
Damage score (SD) (2.53) (2.41) (2.56) (2.01) (7.14) (3.54) (7.10) (5.51) (5.95) (3.52) (5.94) (4.72)
p value - 1.21 (0.23) - 2.03 (< 0.05)a - 0.98 (0.33) - 2.05 (< 0.05)a - 1.43 (0.15) - 1.86 (0.07)
RF, rheumatoid factor; anti-CCP, anti-cyclic citrullinated peptide; SD, standard deviation.
aTwo-sample t test, p < 0.05. Group 1 (disease duration ≤ 24 months) had a significantly
higher number of men than did group 2. It is unclear
whether the clinical manifestations of RA, such as joint
erosion, occur earlier in men, leading to an earlier diagnosis,
or if this finding is a result of sampling bias.
Contrary to our expectations, we found no correlation
between the joint damage score and anti-CCP positivity
(p = 0.065) in group 3. However, this may change in
future studies with a larger patient population.
The major limitation of the present study is bias as a
result of treatment strategy. A prospective study would
allow investigation and manipulation of treatment
modalities such as DMARDs, anti-tumor necrosis factor
(anti-TNF) therapy, and systemic glucocorticoids that are
confounding factors for disease outcome. 
The findings of the present study suggest that the
inclusion of anti-CCP in the diagnostic criteria would
promote earlier detection of inflammatory arthritis and
allow the initiation of more aggressive treatment to prevent
joint damage. Our results are consistent with those of
others recommending that anti-CCP be included in the
RA diagnostic criteria and be used as a marker of the
severity of the disease [28-30]. 
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